Specific	O
uptake	O
of	O
1	O
,	O
25-dihydroxycholecalciferol	O
by	O
human	B-cell_type
chronic	I-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
examined	O
mononuclear	B-cell_line
cell	I-cell_line
preparations	I-cell_line
from	O
patients	O
with	O
chronic	O
myeloid	O
leukemia	O
[	O
CML	O
]	O
for	O
binding	O
of	O
and	O
response	O
to	O
1	O
,	O
25-dihydroxycholecalciferol	O
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
.	O

Whole	O
cells	O
specifically	O
took	O
up	O
[	O
3H	O
]	O
-1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
with	O
high	O
affinity	O
(	O
Kd	O
3.6	O
X	O
10	O
(	O
-11	O
)	O
M	O
)	O
and	O
low	O
capacity	O
.	O

Subcellular	O
fractionation	O
of	O
labeled	B-cell_line
cells	I-cell_line
showed	O
that	O
binding	O
was	O
restricted	O
to	O
cytosols	O
and	O
nuclei	O
.	O

Sucrose	O
gradient	O
centrifugation	O
of	O
cells	O
preincubated	O
with	O
[	O
3H	O
]	O
-1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
revealed	O
a	O
single	O
3.6S	O
peak	O
which	O
was	O
totally	O
displaced	O
with	O
100-fold	O
excess	O
nonradioactive	O
hormone	O
.	O

However	O
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
specific	O
binding	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
by	O
postlabeling	O
standard	O
cytosol	O
preparations	O
.	O

In	O
addition	O
,	O
cytosols	O
prepared	O
from	O
a	O
mixture	O
of	O
CML	B-cell_line
cells	I-cell_line
and	O
1	B-cell_line
,	I-cell_line
25-	I-cell_line
(	I-cell_line
OH	I-cell_line
)	I-cell_line
2D3	I-cell_line
receptor-positive	I-cell_line
T47D	I-cell_line
(	O
human	O
breast	O
cancer	O
)	O
cells	O
had	O
less	O
than	O
10	O
%	O
of	O
the	O
binding	O
measured	O
in	O
T47D	B-cell_line
cytosol	O
alone	O
.	O

However	O
,	O
the	O
levels	O
of	O
binding	O
in	O
T47D	B-cell_line
cytosols	O
were	O
not	O
reduced	O
if	O
the	O
receptors	O
were	O
occupied	O
with	O
[	O
3H	O
]	O
-1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
prior	O
to	O
the	O
addition	O
of	O
the	O
CML	B-cell_line
cytosols	O
.	O

Thus	O
,	O
CML	B-cell_line
cells	I-cell_line
appear	O
to	O
contain	O
both	O
the	O
receptor	O
for	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
and	O
an	O
unknown	O
substance	O
which	O
prevents	O
its	O
detection	O
following	O
the	O
preparation	O
of	O
cytosol	O
.	O

Cells	O
from	O
patients	O
with	O
CML	O
in	O
the	O
chronic	O
phase	O
specifically	O
bound	O
more	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
[	O
18.0	O
+/-	O
3.2	O
(	O
S.E.	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
]	O
than	O
did	O
those	O
in	O
acute	O
myeloid	O
transformation	O
[	O
7.2	O
+/-	O
1.5	O
]	O
or	O
than	O
did	O
cells	O
from	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
[	O
2.6	O
+/-	O
0.8	O
]	O
.	O

Only	O
cells	O
from	O
the	O
first	O
group	O
of	O
patients	O
responded	O
to	O
the	O
addition	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
by	O
differentiating	O
along	O
the	O
monocyte-macrophage	O
pathway	O
.	O

We	O
conclude	O
that	O
the	O
differentiation-induction	O
effect	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
is	O
likely	O
to	O
depend	O
on	O
adequate	O
levels	O
of	O
receptor	O
and	O
that	O
intact	B-cell_type
cells	I-cell_type
rather	O
than	O
cytosol	O
preparations	O
should	O
be	O
studied	O
before	O
cells	O
of	O
a	O
particular	O
tissue	O
are	O
designated	O
as	O
receptor	O
negative	O
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
44	NULL
,	NULL
3627-3631	NULL
,	NULL
August	NULL
1984	NULL
]	NULL
Specific	NULL
Uptake	NULL
of	NULL
1,25-Dihydroxycholecalciferol	NULL
by	NULL
Human	NULL
Chronic	NULL
Myeloid	NULL
Leukemia	NULL
Cells	NULL
H.	NULL
C.	NULL
Freake	NULL
,	NULL
'	NULL
J.	NULL
Iwasaki	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
McCarthy®	NULL
Department	NULL
of	NULL
Chemical	NULL
Pathology	NULL
[	NULL
H.	NULL
C.	NULL
F.	NULL
,	NULL
J	NULL
.	NULL

I	NULL
.	NULL
]	NULL

and	NULL
the	NULL
MRC	NULL
Leukaemia	NULL
Unit	NULL
and	NULL
Department	NULL
of	NULL
Haematology	NULL
[	NULL
D.	NULL
M.	NULL
M.	NULL
]	NULL
,	NULL
Royal	NULL
Postgraduate	NULL
Medical	NULL
School	NULL
,	NULL
Ducane	NULL
Road	NULL
,	NULL
London	NULL
,	NULL
W12	NULL
OHS	NULL
,	NULL
United	NULL
Kingdom	NULL
ABSTRACT	NULL
We	NULL
have	NULL
examined	NULL
mononuclear	NULL
cell	NULL
preparations	NULL
from	NULL
patients	NULL
with	NULL
chronic	NULL
myeloid	NULL
leukemia	NULL
[	NULL
CML	NULL
]	NULL
for	NULL
binding	NULL
of	NULL
and	NULL
response	NULL
to	NULL
1,25-dihydroxycholecalciferol	NULL
[	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
]	NULL
.	NULL

Whole	NULL
cells	NULL
specifically	NULL
took	NULL
up	NULL
[	NULL
°H	NULL
}	NULL
]	NULL
-1,25-	NULL
{	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
with	NULL
high	NULL
affinity	NULL
(	NULL
Ky	NULL
3.6	NULL
x	NULL
107	NULL
``	NULL
m	NULL
)	NULL
and	NULL
low	NULL
capacity	NULL
.	NULL

Subcellular	NULL
fractionation	NULL
of	NULL
labeled	NULL
cells	NULL
showed	NULL
that	NULL
binding	NULL
was	NULL
restricted	NULL
to	NULL
cytosols	NULL
and	NULL
nuclei	NULL
.	NULL

Sucrose	NULL
gradient	NULL
centrifugation	NULL
of	NULL
cells	NULL
preincubated	NULL
with	NULL
PH	NULL
]	NULL
-1,25-4	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
revealed	NULL
a	NULL
single	NULL
3.6S	NULL
peak	NULL
which	NULL
was	NULL
totally	NULL
displaced	NULL
with	NULL
100-fold	NULL
excess	NULL
nonradioactive	NULL
hormone	NULL
.	NULL

However	NULL
,	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
demonstrate	NULL
specific	NULL
binding	NULL
of	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
by	NULL
postlabeling	NULL
standard	NULL
cytosol	NULL
preparations	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
cytosols	NULL
prepared	NULL
from	NULL
a	NULL
mixture	NULL
of	NULL
CML	NULL
cells	NULL
and	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
Ds	NULL
receptor-positive	NULL
T47D	NULL
(	NULL
human	NULL
breast	NULL
cancer	NULL
)	NULL
cells	NULL
had	NULL
les	NULL
»	NULL
than	NULL
10	NULL
%	NULL
of	NULL
the	NULL
binding	NULL
measured	NULL
in	NULL
T47D	NULL
cytosol	NULL
alone	NULL
.	NULL

However	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
binding	NULL
in	NULL
T47D	NULL
cytosols	NULL
were	NULL
not	NULL
reduced	NULL
if	NULL
the	NULL
receptors	NULL
were	NULL
occupied	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
CML	NULL
cytosols	NULL
.	NULL

Thus	NULL
,	NULL
CML	NULL
cells	NULL
appear	NULL
to	NULL
contain	NULL
both	NULL
the	NULL
receptor	NULL
for	NULL
1,25	NULL
<	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
and	NULL
an	NULL
unknown	NULL
substance	NULL
which	NULL
prevents	NULL
its	NULL
detection	NULL
following	NULL
the	NULL
preparation	NULL
of	NULL
cytosol	NULL
.	NULL

Cells	NULL
from	NULL
patients	NULL
with	NULL
CML	NULL
in	NULL
the	NULL
chronic	NULL
phase	NULL
specifically	NULL
bound	NULL
more	NULL
[	NULL
18.0	NULL
+	NULL
3.2	NULL
(	NULL
S.E	NULL
.	NULL
)	NULL

fmol/10	NULL
'	NULL
cells	NULL
]	NULL
than	NULL
did	NULL
those	NULL
in	NULL
acute	NULL
myeloid	NULL
transformation	NULL
[	NULL
7.2	NULL
+	NULL
1.5	NULL
]	NULL
or	NULL
than	NULL
did	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
[	NULL
2.6	NULL
+	NULL
0.8	NULL
]	NULL
.	NULL

Only	NULL
cells	NULL
from	NULL
the	NULL
first	NULL
group	NULL
of	NULL
patients	NULL
responded	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
by	NULL
differentiating	NULL
along	NULL
the	NULL
monocyte-macrophage	NULL
pathway	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
the	NULL
differentiation-induction	NULL
effect	NULL
of	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
likely	NULL
to	NULL
depend	NULL
on	NULL
adequate	NULL
levels	NULL
of	NULL
receptor	NULL
and	NULL
that	NULL
intact	NULL
cells	NULL
rather	NULL
than	NULL
cytosol	NULL
preparations	NULL
should	NULL
be	NULL
studied	NULL
before	NULL
cells	NULL
of	NULL
a	NULL
particular	NULL
tissue	NULL
are	NULL
designated	NULL
as	NULL
receptor	NULL
negative	NULL
.	NULL

INTRODUCTION	NULL
Recently	NULL
,	NULL
studies	NULL
on	NULL
the	NULL
distribution	NULL
of	NULL
the	NULL
specific	NULL
binding	NULL
protein	NULL
for	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
°	NULL
have	NULL
suggested	NULL
several	NULL
new	NULL
sites	NULL
of	NULL
action	NULL
for	NULL
this	NULL
calcium-regulating	NULL
hormone	NULL
.	NULL

Ten	NULL
years	NULL
ago	NULL
,	NULL
intes-tine	NULL
,	NULL
bone	NULL
,	NULL
and	NULL
kidney	NULL
were	NULL
the	NULL
only	NULL
target	NULL
tissues	NULL
known	NULL
,	NULL
but	NULL
now	NULL
the	NULL
list	NULL
includes	NULL
other	NULL
calcium-transporting	NULL
organs	NULL
(	NULL
breast	NULL
,	NULL
placenta	NULL
)	NULL
,	NULL
endocrine	NULL
glands	NULL
producing	NULL
hormones	NULL
thought	NULL
to	NULL
*	NULL
Present	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Minnesota	NULL
,	NULL
Minneap-olis	NULL
,	NULL
MN	NULL
.	NULL

*Supported	NULL
by	NULL
the	NULL
Leukaemia	NULL
Research	NULL
Fund	NULL
of	NULL
Great	NULL
Britain	NULL
.	NULL

To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
,	NULL
1,25-dihydroxycholecalciferol	NULL
;	NULL
AML	NULL
.	NULL

,	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
;	NULL
BSA	NULL
,	NULL
bovine	NULL
serum	NULL
albumin	NULL
;	NULL
CML	NULL
,	NULL
chronic	NULL
myeloid	NULL
leukemia	NULL
;	NULL
KTEDMT	NULL
,	NULL
10	NULL
mm	NULL
Tris-HCI	NULL
,	NULL
300	NULL
mm	NULL
KCI	NULL
,	NULL
5	NULL
mm	NULL
dithiothreitol	NULL
,	NULL
10	NULL
mm	NULL
sodium	NULL
molybdate	NULL
Trasylol	NULL
(	NULL
400	NULL
kallikrein-inhibitory	NULL
units/ml	NULL
)	NULL
;	NULL
TEDT	NULL
,	NULL
10	NULL
mm	NULL
Tris-HCH1.5	NULL
glycol	NULL
bis	NULL
(	NULL
G-aminoethy	NULL
!	NULL

ether	NULL
)	NULL
-N.N.N	NULL
'	NULL
,	NULL
N	NULL
'	NULL
-tetraacetic	NULL
acid	NULL
;	NULL
5	NULL
mm	NULL
dithio-thrsutol	NULL
Trasylol	NULL
(	NULL
400	NULL
kallikrein-i	NULL
units/m1	NULL
)	NULL
;	NULL
25-OHD	NULL
,	NULL
25-hydroxydlolecal-ciferol	NULL
;	NULL
[	NULL
PH	NULL
]	NULL
-1,25-	NULL
{	NULL
0H	NULL
)	NULL
;	NULL
D	NULL
,	NULL
,	NULL
1,25-dihydroxy	NULL
[	NULL
26,27-methy	NULL
!	NULL

-	NULL
``	NULL
Hcholecalciferol	NULL
Received	NULL
November	NULL
30	NULL
,	NULL
1983	NULL
;	NULL
accepted	NULL
May	NULL
8	NULL
,	NULL
1984	NULL
.	NULL

AUGUST	NULL
1984	NULL
regulate	NULL
the	NULL
renal	NULL
25-OHDs	NULL
hydroxylases	NULL
(	NULL
parathyroids	NULL
,	NULL
pituitary	NULL
,	NULL
ovary	NULL
,	NULL
etc	NULL
.	NULL
)	NULL

,	NULL
and	NULL
other	NULL
sites	NULL
where	NULL
the	NULL
function	NULL
of	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
is	NULL
more	NULL
obscure	NULL
(	NULL
skin	NULL
,	NULL
brain	NULL
)	NULL
(	NULL
13	NULL
)	NULL
.	NULL

1,25-4	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
receptors	NULL
are	NULL
also	NULL
present	NULL
in	NULL
a	NULL
number	NULL
of	NULL
neo-plastic	NULL
tissues	NULL
and	NULL
in	NULL
cell	NULL
lines	NULL
derived	NULL
from	NULL
them	NULL
(	NULL
4-6	NULL
,	NULL
9	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
the	NULL
receptor	NULL
in	NULL
transformed	NULL
cells	NULL
has	NULL
generally	NULL
been	NULL
assumed	NULL
to	NULL
represent	NULL
a	NULL
retained	NULL
property	NULL
of	NULL
the	NULL
parent	NULL
tissue	NULL
.	NULL

Biological	NULL
effects	NULL
of	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
cancer	NULL
cells	NULL
have	NULL
been	NULL
harder	NULL
to	NULL
demonstrate	NULL
,	NULL
although	NULL
effects	NULL
on	NULL
proliferation	NULL
in	NULL
breast	NULL
(	NULL
8	NULL
)	NULL
,	NULL
melanoma	NULL
(	NULL
3	NULL
)	NULL
,	NULL
and	NULL
bone	NULL
(	NULL
11	NULL
)	NULL
cells	NULL
in	NULL
culture	NULL
have	NULL
now	NULL
been	NULL
seen	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
prior	NULL
to	NULL
the	NULL
demonstration	NULL
of	NULL
a	NULL
receptor	NULL
,	NULL
Abe	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1	NULL
)	NULL
found	NULL
that	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
Ds	NULL
induced	NULL
monncytic	NULL
differentiation	NULL
in	NULL
a	NULL
murine	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
M1	NULL
)	NULL
.	NULL

They	NULL
also	NULL
reported	NULL
that	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
»	NULL
Ds	NULL
caused	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
cells	NULL
from	NULL
a	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL6O0	NULL
)	NULL
and	NULL
showed	NULL
that	NULL
these	NULL
cells	NULL
possessed	NULL
the	NULL
cytosolic	NULL
receptor	NULL
for	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
biological	NULL
effects	NULL
produced	NULL
by	NULL
different	NULL
cholecalciferol	NULL
metabolites	NULL
in	NULL
these	NULL
cells	NULL
correlated	NULL
well	NULL
with	NULL
their	NULL
affinity	NULL
for	NULL
the	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptor	NULL
.	NULL

The	NULL
differentiation	NULL
of	NULL
these	NULL
cells	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
slowing	NULL
of	NULL
proliferation	NULL
,	NULL
and	NULL
the	NULL
potential	NULL
significance	NULL
of	NULL
this	NULL
has	NULL
been	NULL
emphasized	NULL
recently	NULL
by	NULL
the	NULL
same	NULL
group	NULL
's	NULL
demonstration	NULL
of	NULL
prolonged	NULL
survival	NULL
times	NULL
in	NULL
mice	NULL
given	NULL
injections	NULL
of	NULL
M1	NULL
cells	NULL
,	NULL
when	NULL
treated	NULL
with	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
or	NULL
1a-hydrox-ycholecalciferol	NULL
(	NULL
10	NULL
)	NULL
.	NULL

In	NULL
our	NULL
laboratory	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
causes	NULL
monocytic	NULL
differentiation	NULL
of	NULL
HL6O	NULL
cells	NULL
,	NULL
as	NULL
judged	NULL
by	NULL
morphology	NULL
,	NULL
cytochemistry	NULL
,	NULL
and	NULL
the	NULL
presence	NULL
of	NULL
specific	NULL
surface	NULL
antigens	NULL
.	NULL

We	NULL
have	NULL
also	NULL
seen	NULL
similar	NULL
effects	NULL
in	NULL
normal	NULL
bone	NULL
marrow	NULL
(	NULL
12	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
Bar-Shavit	NULL
et	NULL
al	NULL
.	NULL

(	NULL
2	NULL
)	NULL
have	NULL
recently	NULL
demonstrated	NULL
1,25-monocytic	NULL
differentiation	NULL
of	NULL
HLG6O	NULL
.	NULL

We	NULL
here	NULL
report	NULL
the	NULL
characterization	NULL
of	NULL
specific	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
uptake	NULL
and	NULL
response	NULL
of	NULL
mononuclear	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
myeloid	NULL
leu-kemias	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
[	NULL
PH	NULL
]	NULL
-1,25-	NULL
(	NULL
O0H	NULL
)	NULL
D	NULL
;	NULL
(	NULL
specific	NULL
radioactivity	NULL
,	NULL
163	NULL
Ci/mmol	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Amersham	NULL
International	NULL
(	NULL
Amersham	NULL
,	NULL
Buckinghamshire	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
.	NULL

Nonradioactive	NULL
cholecaiciferol	NULL
metabolites	NULL
were	NULL
a	NULL
gift	NULL
from	NULL
Roche	NULL
Products	NULL
(	NULL
Welwyn	NULL
Garden	NULL
City	NULL
,	NULL
Hertsfordshire	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
.	NULL

Reagents	NULL
were	NULL
of	NULL
analytical	NULL
grade	NULL
and	NULL
were	NULL
obtained	NULL
from	NULL
commercial	NULL
suppliers	NULL
.	NULL

Bone	NULL
marrow	NULL
or	NULL
buffy	NULL
coat	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
patients	NULL
with	NULL
Philadelphia	NULL
chromosome-positive	NULL
CML	NULL
when	NULL
they	NULL
were	NULL
either	NULL
in	NULL
the	NULL
chronic	NULL
stage	NULL
of	NULL
their	NULL
disease	NULL
or	NULL
in	NULL
acute	NULL
myeloid	NULL
transformation	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
also	NULL
obtained	NULL
from	NULL
patients	NULL
with	NULL
AML	NULL
.	NULL

The	NULL
mononuclear	NULL
fraction	NULL
was	NULL
prepared	NULL
by	NULL
layering	NULL
the	NULL
cell	NULL
suspension	NULL
onto	NULL
Lymphoprep	NULL
(	NULL
Nyegaard	NULL
,	NULL
Ltd.	NULL
,	NULL
Oslo	NULL
,	NULL
Norway	NULL
)	NULL
,	NULL
centrifuging	NULL
at	NULL
400	NULL
x	NULL
g	NULL
for	NULL
25	NULL
min	NULL
,	NULL
and	NULL
collecting	NULL
the	NULL
cells	NULL
at	NULL
the	NULL
interface	NULL
.	NULL

Cytosol	NULL
Binding	NULL
Studies	NULL
.	NULL

Cells	NULL
were	NULL
initially	NULL
examined	NULL
for	NULL
specific	NULL
3627	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

H.	NULL
C.	NULL
Freake	NULL
et	NULL
al	NULL
.	NULL

cytosolic	NULL
binding	NULL
of	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
.	NULL

Cytosols	NULL
were	NULL
prepared	NULL
by	NULL
sonicating	NULL
cells	NULL
(	NULL
2	NULL
to	NULL
5	NULL
x	NULL
10	NULL
``	NULL
/mi	NULL
)	NULL
on	NULL
ice	NULL
in	NULL
a	NULL
Tris	NULL
buffer	NULL
(	NULL
KTEDMT	NULL
)	NULL
known	NULL
to	NULL
optimize	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptor	NULL
measurement	NULL
in	NULL
other	NULL
systems	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
homog-enates	NULL
were	NULL
centrifuged	NULL
at	NULL
88,000	NULL
x	NULL
g	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°	NULL
in	NULL
the	NULL
70Ti	NULL
rotor	NULL
of	NULL
a	NULL
Beckman	NULL
L8	NULL
70	NULL
ultracentrifuge	NULL
.	NULL

Binding	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
was	NULL
assayed	NULL
in	NULL
these	NULL
cytosols	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Whole-Cell	NULL
Uptake	NULL
.	NULL

Specific	NULL
uptake	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
by	NULL
intact	NULL
cell	NULL
preparations	NULL
was	NULL
determined	NULL
largely	NULL
as	NULL
described	NULL
by	NULL
Sher	NULL
et	NULL
a/	NULL
.	NULL

(	NULL
18	NULL
)	NULL
,	NULL
except	NULL
that	NULL
a	NULL
shorter	NULL
incubation	NULL
time	NULL
was	NULL
found	NULL
to	NULL
be	NULL
sufficient	NULL
to	NULL
maximize	NULL
binding	NULL
.	NULL

Cells	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
suspended	NULL
in	NULL
triplicate	NULL
for	NULL
3	NULL
hr	NULL
at	NULL
37°	NULL
in	NULL
0.5	NULL
mi	NULL
RPMI	NULL
1640	NULL
plus	NULL
0.05	NULL
%	NULL
BSA	NULL
with	NULL
0.1	NULL
pmo	NULL
!	NULL

PH	NULL
]	NULL
-1,25-	NULL
(	NULL
OH	NULL
)	NULL
Ds	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
10	NULL
pmol	NULL
1,25-	NULL
{	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
,	NULL
or	NULL
25-OHDs	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
the	NULL
incubation	NULL
,	NULL
cells	NULL
were	NULL
spun	NULL
down	NULL
(	NULL
800	NULL
x	NULL
g	NULL
,	NULL
5	NULL
min	NULL
)	NULL
and	NULL
resuspended	NULL
in	NULL
0.5	NULL
ml	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
8	NULL
g	NULL
NaCI	NULL
,	NULL
0.2	NULL
g	NULL
KCI	NULL
,	NULL
and	NULL
0.2	NULL
g	NULL
NaHPO	NULL
,	NULL
in	NULL
100	NULL
mi	NULL
distilled	NULL
HO	NULL
)	NULL
containing	NULL
0.5	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
BSA	NULL
for	NULL
20	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
suspensions	NULL
were	NULL
pelleted	NULL
,	NULL
rinsed	NULL
once	NULL
more	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
alone	NULL
,	NULL
and	NULL
then	NULL
dissolved	NULL
in	NULL
0.5	NULL
ml	NULL
1	NULL
m	NULL
NaOH	NULL
.	NULL

The	NULL
pH	NULL
was	NULL
corrected	NULL
to	NULL
7.4	NULL
with	NULL
glacial	NULL
acetic	NULL
acid	NULL
,	NULL
prior	NULL
to	NULL
counting	NULL
in	NULL
10	NULL
ml	NULL
scintillant	NULL
ES299	NULL
(	NULL
Packard	NULL
Instruments	NULL
,	NULL
Caversham	NULL
,	NULL
Berkshire	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
using	NULL
a	NULL
Packard	NULL
Tri-Carb	NULL
liquid	NULL
scintillation	NULL
counter	NULL
with	NULL
an	NULL
efficiency	NULL
for	NULL
tritium	NULL
of	NULL
30	NULL
%	NULL
.	NULL

Further	NULL
competition	NULL
studies	NULL
were	NULL
performed	NULL
on	NULL
some	NULL
preparations	NULL
by	NULL
incubating	NULL
cells	NULL
,	NULL
as	NULL
described	NULL
above	NULL
,	NULL
with	NULL
0.06	NULL
pmol	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
{	NULL
OH	NULL
)	NULL
:	NULL
Ds	NULL
;	NULL
and	NULL
increasing	NULL
amounts	NULL
of	NULL
cholecalciferol	NULL
,	NULL
its	NULL
metabolites	NULL
,	NULL
or	NULL
other	NULL
steroids	NULL
(	NULL
10~®	NULL
to	NULL
10~	NULL
``	NULL
``	NULL
mol	NULL
)	NULL
.	NULL

The	NULL
affinity	NULL
between	NULL
CML	NULL
cells	NULL
and	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
was	NULL
determined	NULL
by	NULL
incubating	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
)	NULL
with	NULL
increasing	NULL
amounts	NULL
(	NULL
0.01	NULL
to	NULL
0.15	NULL
pmol	NULL
)	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
for	NULL
3	NULL
hr	NULL
at	NULL
37°	NULL
;	NULL
parallel	NULL
incubations	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100-fold	NULL
excess	NULL
nonradioactive	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
.D	NULL
;	NULL
were	NULL
used	NULL
to	NULL
determine	NULL
nonspecific	NULL
uptake	NULL
.	NULL

Cells	NULL
were	NULL
processed	NULL
prior	NULL
to	NULL
liquid	NULL
scintillation	NULL
counting	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Data	NULL
were	NULL
analyzed	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Scatchard	NULL
(	NULL
16	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
cytosols	NULL
were	NULL
prepared	NULL
as	NULL
before	NULL
from	NULL
cells	NULL
prelabeled	NULL
with	NULL
0.1	NULL
pmol	NULL
!	NULL

+	NULL
10	NULL
(	NULL
S.E	NULL
.	NULL
)	NULL

pmol	NULL
,	NULL
1,25	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
or	NULL
25-OHDs	NULL
at	NULL
37°	NULL
for	NULL
3	NULL
hr	NULL
.	NULL

The	NULL
cytosols	NULL
were	NULL
applied	NULL
to	NULL
5	NULL
to	NULL
20	NULL
%	NULL
sucrose	NULL
gradients	NULL
(	NULL
w/v	NULL
in	NULL
KTEDMT	NULL
)	NULL
and	NULL
spun	NULL
at	NULL
288,000	NULL
x	NULL
g	NULL
for	NULL
15	NULL
hr	NULL
at	NULL
4°	NULL
in	NULL
the	NULL
SW55	NULL
rotor	NULL
of	NULL
a	NULL
Beckman	NULL
L870	NULL
ultracentrifuge	NULL
.	NULL

Gradients	NULL
were	NULL
divided	NULL
into	NULL
150-4l	NULL
fractions	NULL
from	NULL
the	NULL
bottom	NULL
by	NULL
downward	NULL
displacement	NULL
with	NULL
mineral	NULL
oil	NULL
.	NULL

Subcellular	NULL
Localization	NULL
.	NULL

Cells	NULL
which	NULL
had	NULL
been	NULL
incubated	NULL
with	NULL
tritiated	NULL
hormone	NULL
and	NULL
rinsed	NULL
as	NULL
described	NULL
were	NULL
homogenized	NULL
by	NULL
resus-pending	NULL
in	NULL
hypotonic	NULL
buffer	NULL
(	NULL
TEDT	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
10	NULL
passages	NULL
through	NULL
a	NULL
25-gauge	NULL
needle	NULL
.	NULL

This	NULL
procedure	NULL
lysed	NULL
more	NULL
than	NULL
95	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

KCI	NULL
in	NULL
TEDT	NULL
was	NULL
added	NULL
to	NULL
give	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.15	NULL
m	NULL
KCI	NULL
.	NULL

Homog-enates	NULL
were	NULL
spun	NULL
at	NULL
800	NULL
x	NULL
g	NULL
for	NULL
5	NULL
min	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
recentrifuged	NULL
at	NULL
88,000	NULL
x	NULL
g	NULL
for	NULL
30	NULL
min	NULL
to	NULL
yield	NULL
a	NULL
clear	NULL
cytosol	NULL
and	NULL
a	NULL
pellet	NULL
which	NULL
was	NULL
presumed	NULL
to	NULL
consist	NULL
largely	NULL
of	NULL
mitochondria	NULL
and	NULL
microsomes	NULL
.	NULL

The	NULL
800	NULL
x	NULL
g	NULL
pellet	NULL
was	NULL
rinsed	NULL
in	NULL
TEDT	NULL
,	NULL
recentrifuged	NULL
,	NULL
and	NULL
suspended	NULL
in	NULL
1	NULL
m	NULL
sucrose	NULL
in	NULL
TEDT	NULL
.	NULL

This	NULL
was	NULL
layered	NULL
onto	NULL
a	NULL
sucrose	NULL
pad	NULL
(	NULL
1.7	NULL
m	NULL
sucrose	NULL
in	NULL
TEDT	NULL
)	NULL
and	NULL
centrifuged	NULL
at	NULL
30,000	NULL
x	NULL
g	NULL
for	NULL
20	NULL
min	NULL
.	NULL

The	NULL
sucrose	NULL
buffers	NULL
were	NULL
aspirated	NULL
to	NULL
leave	NULL
a	NULL
pellet	NULL
of	NULL
semipurified	NULL
nuclei	NULL
,	NULL
which	NULL
were	NULL
resuspended	NULL
in	NULL
KTEDMT	NULL
and	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
20	NULL
min	NULL
.	NULL

They	NULL
were	NULL
recentrifuged	NULL
at	NULL
800	NULL
x	NULL
g	NULL
,	NULL
and	NULL
the	NULL
radioactivities	NULL
in	NULL
the	NULL
supernatants	NULL
and	NULL
pellets	NULL
were	NULL
counted	NULL
separately	NULL
.	NULL

Combination	NULL
Experiments	NULL
.	NULL

in	NULL
an	NULL
attempt	NULL
to	NULL
explain	NULL
the	NULL
apparent	NULL
lack	NULL
of	NULL
specific	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
{	NULL
/OH	NULL
)	NULL
D	NULL
;	NULL
binding	NULL
in	NULL
CML	NULL
cytosols	NULL
,	NULL
specific	NULL
binding	NULL
of	NULL
the	NULL
hormone	NULL
to	NULL
cytosols	NULL
prepared	NULL
from	NULL
a	NULL
receptor-positive	NULL
human	NULL
breast	NULL
cancer	NULL
cell	NULL
line	NULL
[	NULL
T47D	NULL
(	NULL
8	NULL
)	NULL
]	NULL
was	NULL
measured	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
CML	NULL
cytosol	NULL
.	NULL

T47D	NULL
cells	NULL
were	NULL
grown	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
8	NULL
)	NULL
,	NULL
suspended	NULL
in	NULL
KTEDMT	NULL
(	NULL
2	NULL
x	NULL
10	NULL
``	NULL
cells/ml	NULL
)	NULL
and	NULL
mixed	NULL
with	NULL
either	NULL
CML	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
10	NULL
``	NULL
cells/ml	NULL
)	NULL
or	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
BSA	NULL
(	NULL
1	NULL
mg/ml	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
suspensions	NULL
were	NULL
sonicated	NULL
,	NULL
and	NULL
cytosols	NULL
were	NULL
prepared	NULL
and	NULL
assayed	NULL
for	NULL
specific	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
binding	NULL
as	NULL
before	NULL
.	NULL

Cell	NULL
Differentiation	NULL
.	NULL

Cells	NULL
from	NULL
patients	NULL
with	NULL
CML	NULL
or	NULL
AML	NULL
were	NULL
incubated	NULL
with	NULL
107°	NULL
to	NULL
107°	NULL
m	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
or	NULL
25-OHDs	NULL
as	NULL
described	NULL
previously	NULL
for	NULL
normal	NULL
bone	NULL
marrow	NULL
and	NULL
HLGO	NULL
cells	NULL
;	NULL
they	NULL
were	NULL
character	NULL
3628	NULL
IOOPN	NULL
A	NULL
®	NULL
u	NULL
+	NULL
E	NULL
\	NULL
3	NULL
E	NULL
3	NULL
E	NULL
``	NULL
s	NULL
#	NULL
so|-T	NULL
C	NULL
a	NULL
P-	NULL
]	NULL
cm	NULL
AN	NULL
3	NULL
.	NULL

Nu	NULL
(	NULL
h	NULL
0	NULL
L\l-	NULL
.	NULL

|	NULL
€	NULL
.	NULL

0	NULL
10	NULL
“	NULL
1024	NULL
ao	NULL
?	NULL

ao	NULL
``	NULL
as	NULL
``	NULL
as	NULL
°	NULL
10°	NULL
Competing	NULL
Ilgand	NULL
{	NULL
mot	NULL
/tube	NULL
Chart	NULL
1	NULL
.	NULL

Competition	NULL
for	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
{	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
,	NULL
uptake	NULL
into	NULL
whole	NULL
CML	NULL
cells	NULL
.	NULL

CML	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
duplicate	NULL
for	NULL
3	NULL
hr	NULL
at	NULL
37°	NULL
with	NULL
0.06	NULL
pmol	NULL
(	NULL
°H	NULL
]	NULL
-1,25-	NULL
(	NULL
OH	NULL
)	NULL
@	NULL
D	NULL
,	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
various	NULL
amounts	NULL
(	NULL
10~	NULL
``	NULL
to	NULL
107*	NULL
m	NULL
)	NULL
of	NULL
cholecalciferol	NULL
or	NULL
its	NULL
metabolites	NULL
.	NULL

Cells	NULL
were	NULL
rinsed	NULL
twice	NULL
,	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
radioactivity	NULL
oontamedunmemwasassessedbybquldsanﬁllahoncmmw	NULL
Results	NULL
are	NULL
expressed	NULL
as	NULL
percentage	NULL
of	NULL
maximum	NULL
specific	NULL
binding	NULL
,	NULL
/.e	NULL
.	NULL

,	NULL
the	NULL
difference	NULL
between	NULL
binding	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
nonradioactive	NULL
1,25-	NULL
(	NULL
OH	NULL
}	NULL
Ds	NULL
.	NULL

Competing	NULL
steroids	NULL
were	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
Ds	NULL
(	NULL
@	NULL
)	NULL
,	NULL
25-OHD	NULL
;	NULL
(	NULL
A	NULL
)	NULL
,	NULL
24,25-dihydrox-ycholecalciferol	NULL
(	NULL
I	NULL
)	NULL
,	NULL
or	NULL
cholecalciferol	NULL
(	NULL
®	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
seen	NULL
with	NULL
cells	NULL
from	NULL
3	NULL
other	NULL
CML	NULL
patients	NULL
in	NULL
chronic	NULL
phase	NULL
.	NULL

ized	NULL
morphologically	NULL
,	NULL
enzymatically	NULL
,	NULL
and	NULL
by	NULL
reactivity	NULL
with	NULL
monocyte-	NULL
or	NULL
granulocyte-specific	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
12	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
being	NULL
reported	NULL
fully	NULL
elsewhere	NULL
.	NULL

*	NULL
However	NULL
,	NULL
as	NULL
an	NULL
index	NULL
of	NULL
monocytic	NULL
differentiation	NULL
,	NULL
the	NULL
percentage	NULL
of	NULL
cells	NULL
containing	NULL
fluoride-sensitive	NULL
a-naphthyl	NULL
acetate	NULL
esterase	NULL
(	NULL
22	NULL
)	NULL
was	NULL
used	NULL
.	NULL

RESULTS	NULL
Despite	NULL
clear	NULL
evidence	NULL
of	NULL
biological	NULL
activity	NULL
of	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
CML	NULL
cells	NULL
,	NULL
only	NULL
low	NULL
to	NULL
undetectable	NULL
levels	NULL
of	NULL
specific	NULL
binding	NULL
(	NULL
200	NULL
cpm/10	NULL
``	NULL
cells	NULL
)	NULL
could	NULL
be	NULL
measured	NULL
in	NULL
cytosol	NULL
preparations	NULL
,	NULL
using	NULL
buffers	NULL
and	NULL
assay	NULL
conditions	NULL
found	NULL
optimal	NULL
for	NULL
the	NULL
receptor	NULL
measured	NULL
in	NULL
other	NULL
cytosols	NULL
.	NULL

The	NULL
level	NULL
of	NULL
binding	NULL
was	NULL
not	NULL
enhanced	NULL
by	NULL
increasing	NULL
the	NULL
concentration	NULL
of	NULL
protease	NULL
inhibitor	NULL
(	NULL
Trasylol	NULL
)	NULL
in	NULL
the	NULL
buffer	NULL
.	NULL

As	NULL
a	NULL
consequence	NULL
,	NULL
the	NULL
specific	NULL
uptake	NULL
of	NULL
{	NULL
°H	NULL
]	NULL
-1,25-4	NULL
{	NULL
O0H	NULL
)	NULL
D	NULL
;	NULL
by	NULL
intact	NULL
cells	NULL
was	NULL
examined	NULL
.	NULL

CML	NULL
cells	NULL
incubated	NULL
at	NULL
37°	NULL
accumulated	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
in	NULL
a	NULL
time-dependent	NULL
manner	NULL
,	NULL
reaching	NULL
a	NULL
maximum	NULL
by	NULL
2	NULL
hr	NULL
,	NULL
which	NULL
was	NULL
maintained	NULL
for	NULL
at	NULL
least	NULL
6	NULL
hr	NULL
.	NULL

This	NULL
uptake	NULL
was	NULL
partially	NULL
displaceable	NULL
by	NULL
100-fold	NULL
excess	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
but	NULL
not	NULL
by	NULL
25-OHDs	NULL
.	NULL

Competition	NULL
studies	NULL
using	NULL
multiple	NULL
concentrations	NULL
of	NULL
cholecaiciferol	NULL
metabolites	NULL
showed	NULL
that	NULL
both	NULL
25-O0HD	NULL
;	NULL
and	NULL
24,25-dihydroxycholecaliciferol	NULL
could	NULL
block	NULL
the	NULL
specific	NULL
uptake	NULL
of	NULL
the	NULL
label	NULL
,	NULL
but	NULL
only	NULL
at	NULL
concentrations	NULL
200	NULL
to	NULL
1000	NULL
times	NULL
higher	NULL
than	NULL
that	NULL
required	NULL
with	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
Chart	NULL
1	NULL
)	NULL
.	NULL

Cholecalciferol	NULL
,	NULL
estra-diol	NULL
,	NULL
and	NULL
hydrocortisone	NULL
(	NULL
107°	NULL
m	NULL
)	NULL
were	NULL
all	NULL
incapable	NULL
of	NULL
reducing	NULL
the	NULL
uptake	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
}	NULL
-1,25-	NULL
(	NULL
OH	NULL
)	NULL
Ds	NULL
.	NULL

The	NULL
affinity	NULL
of	NULL
this	NULL
interaction	NULL
between	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
CML	NULL
cells	NULL
was	NULL
assessed	NULL
using	NULL
Scatchard	NULL
analysis	NULL
of	NULL
saturation	NULL
plots	NULL
(	NULL
Chart	NULL
2	NULL
)	NULL
.	NULL

An	NULL
equilibrium	NULL
dissociation	NULL
constant	NULL
of	NULL
5.4	NULL
+	NULL
1.4	NULL
(	NULL
S.E	NULL
.	NULL
)	NULL

x	NULL
10-	NULL
``	NULL
``	NULL
'	NULL
m.	NULL
(	NULL
n	NULL
=	NULL
3	NULL
)	NULL
was	NULL
calculated	NULL
.	NULL

The	NULL
subcellular	NULL
location	NULL
of	NULL
the	NULL
saturable	NULL
portion	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
*	NULL
D.	NULL
M.	NULL
McCarthy	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Hebber	NULL
,	NULL
J.	NULL
F.	NULL
San	NULL
Miguel	NULL
,	NULL
B.	NULL
Rodriques	NULL
,	NULL
C.	NULL
Andrews	NULL
,	NULL
D.	NULL
Catovsky	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Goldman	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
vitamin	NULL
Ds	NULL
;	NULL
metabolites	NULL
on	NULL
normal	NULL
and	NULL
leukemic	NULL
bone	NULL
marrow	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Cloning	NULL
,	NULL
2	NULL
:	NULL
227-242	NULL
,	NULL
1984	NULL
.	NULL

CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

44	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

18	NULL
bit	NULL
0.6	NULL
6	NULL
A//	NULL
.	NULL

A/	NULL
3\	NULL
PJ	NULL
-1	NULL
,	NULL
25-10H	NULL
,	NULL
D	NULL
,	NULL
bound	NULL
.	NULL

(	NULL
fmolitube	NULL
)	NULL
o	NULL
F	NULL
|	NULL
po	NULL
0	NULL
1	NULL
|	NULL
j	NULL
0.0	NULL
-	NULL
0.08	NULL
0.12	NULL
a	NULL
3	NULL
12	NULL
Pua	NULL
,	NULL
25-10H0	NULL
,	NULL
D	NULL
,	NULL
added	NULL
Pu	NULL
,	NULL
25-10H	NULL
)	NULL
,	NULL
D	NULL
,	NULL
bound	NULL
(	NULL
pmol/tube	NULL
)	NULL
{	NULL
fmol/tube	NULL
)	NULL
Chart	NULL
2	NULL
.	NULL

Saturation	NULL
analysis	NULL
of	NULL
{	NULL
°H	NULL
}	NULL
-1,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
0D	NULL
,	NULL
uptake	NULL
by	NULL
CML	NULL
cells	NULL
.	NULL

CML	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
duplicate	NULL
with	NULL
increasing	NULL
amounts	NULL
(	NULL
0.01	NULL
to	NULL
0.15	NULL
pmo	NULL
!	NULL
)	NULL

of	NULL
[	NULL
°H	NULL
}	NULL
-1,25-	NULL
{	NULL
OH	NULL
)	NULL
.Ds	NULL
alone	NULL
(	NULL
&	NULL
,	NULL
total	NULL
binding	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100-fold	NULL
excess	NULL
nonradioactive	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
.D	NULL
,	NULL
(	NULL
A	NULL
,	NULL
nonspecific	NULL
binding	NULL
)	NULL
for	NULL
3	NULL
hr	NULL
at	NULL
37°	NULL
.	NULL

The	NULL
difference	NULL
in	NULL
uptake	NULL
between	NULL
the	NULL
2	NULL
(	NULL
®	NULL
,	NULL
specific	NULL
binding	NULL
)	NULL
was	NULL
used	NULL
to	NULL
generate	NULL
the	NULL
Scatchard	NULL
plot	NULL
shown	NULL
on	NULL
the	NULL
right	NULL
.	NULL

K	NULL
,	NULL
=	NULL
3.6	NULL
X	NULL
107	NULL
``	NULL
M.	NULL
N=	NULL
,	NULL
=	NULL
29.3	NULL
fmol/10	NULL
``	NULL
calls	NULL
.	NULL

bif	NULL
,	NULL
bound/free	NULL
.	NULL

so	NULL
1	NULL
100	NULL
|-	NULL
A\.\	NULL
.	NULL

Cl	NULL
A	NULL
I\	NULL
im	NULL
:	NULL
Q	NULL
;	NULL
0	NULL
T.	NULL
--	NULL
--	NULL
--	NULL
-=	NULL
>	NULL
e==aeaessssasszsﬁi	NULL
Chart	NULL
3	NULL
.	NULL

Sucrose	NULL
density	NULL
gradient	NULL
analysis	NULL
of	NULL
[	NULL
PH	NULL
]	NULL
-1,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
Ds	NULL
binding	NULL
in	NULL
CML	NULL
cells	NULL
.	NULL

CML	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
[	NULL
PH	NULL
]	NULL
-1,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
,	NULL
(	NULL
0.1	NULL
pmol	NULL
)	NULL
alone	NULL
(	NULL
@	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
pmol	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
0	NULL
)	NULL
or	NULL
25-OHD	NULL
;	NULL
(	NULL
A	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
rinsed	NULL
twice	NULL
,	NULL
and	NULL
cytosols	NULL
were	NULL
prepared	NULL
by	NULL
sonication	NULL
in	NULL
KTEDMT	NULL
,	NULL
followed	NULL
by	NULL
ultracentrifu-	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
cells	NULL
were	NULL
homogenized	NULL
,	NULL
and	NULL
then	NULL
the	NULL
cytosols	NULL
were	NULL
incubated	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
{	NULL
0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
fll	NULL
)	NULL
.	NULL

All	NULL
cytosols	NULL
were	NULL
applied	NULL
to	NULL
5	NULL
to	NULL
20	NULL
%	NULL
sucrose	NULL
gradients	NULL
and	NULL
centrifuged	NULL
at	NULL
288,000	NULL
x	NULL
g	NULL
for	NULL
14	NULL
hr	NULL
at	NULL
4°	NULL
.	NULL

They	NULL
were	NULL
divided	NULL
into	NULL
150-41	NULL
fractions	NULL
from	NULL
the	NULL
bottom	NULL
.	NULL

Arrow	NULL
,	NULL
position	NULL
of	NULL
``	NULL
*C-ovalbumin	NULL
(	NULL
3.78	NULL
)	NULL
run	NULL
in	NULL
a	NULL
parallel	NULL
gradient	NULL
.	NULL

T	NULL
,	NULL
top	NULL
fraction	NULL
;	NULL
B	NULL
,	NULL
bottom	NULL
fraction	NULL
.	NULL

uptake	NULL
was	NULL
determined	NULL
under	NULL
isotonic	NULL
conditions	NULL
by	NULL
separating	NULL
cells	NULL
labeled	NULL
with	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
excess	NULL
competing	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
or	NULL
25-O0HD	NULL
;	NULL
into	NULL
AUGUST	NULL
1984	NULL
Specific	NULL
Uptake	NULL
of	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
»	NULL
D	NULL
;	NULL
by	NULL
CML	NULL
Cells	NULL
cytosols	NULL
,	NULL
mitochondria-microsomes	NULL
,	NULL
0.3	NULL
m	NULL
KCI	NULL
nuclear	NULL
extracts	NULL
,	NULL
and	NULL
residual	NULL
nuclei	NULL
.	NULL

Specific	NULL
binding	NULL
was	NULL
restricted	NULL
to	NULL
cytosols	NULL
(	NULL
29	NULL
%	NULL
)	NULL
,	NULL
nuclear	NULL
extracts	NULL
(	NULL
29	NULL
%	NULL
)	NULL
,	NULL
and	NULL
nuclear	NULL
residues	NULL
(	NULL
41	NULL
%	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
labeled	NULL
cells	NULL
were	NULL
homogenized	NULL
by	NULL
sonication	NULL
in	NULL
hypertonic	NULL
buffer	NULL
,	NULL
cytosols	NULL
were	NULL
prepared	NULL
,	NULL
and	NULL
the	NULL
radioactivity	NULL
in	NULL
them	NULL
was	NULL
analyzed	NULL
by	NULL
sucrose	NULL
density	NULL
gradient	NULL
ultracentrifu-gation	NULL
.	NULL

A	NULL
single	NULL
peak	NULL
was	NULL
seen	NULL
,	NULL
migrating	NULL
one	NULL
fraction	NULL
later	NULL
than	NULL
the	NULL
3.78	NULL
marker	NULL
,	NULL
which	NULL
was	NULL
totally	NULL
abolished	NULL
when	NULL
cells	NULL
were	NULL
preincubated	NULL
with	NULL
excess	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
but	NULL
only	NULL
slightly	NULL
reduced	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
excess	NULL
25-O0HD	NULL
,	NULL
(	NULL
Chart	NULL
3	NULL
)	NULL
.	NULL

No	NULL
peak	NULL
was	NULL
visible	NULL
when	NULL
cytosols	NULL
were	NULL
incubated	NULL
directly	NULL
with	NULL
tritiated	NULL
hormone	NULL
.	NULL

The	NULL
specific	NULL
uptake	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
by	NULL
CML	NULL
cells	NULL
thus	NULL
appeared	NULL
to	NULL
be	NULL
due	NULL
to	NULL
a	NULL
binding	NULL
moiety	NULL
with	NULL
the	NULL
characteristics	NULL
of	NULL
the	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptor	NULL
found	NULL
in	NULL
other	NULL
tissues	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
discover	NULL
why	NULL
the	NULL
receptor	NULL
was	NULL
not	NULL
measurable	NULL
in	NULL
standard	NULL
cytosol	NULL
preparations	NULL
,	NULL
such	NULL
cytosols	NULL
were	NULL
mixed	NULL
with	NULL
those	NULL
from	NULL
the	NULL
receptor-positive	NULL
T47D	NULL
cells	NULL
and	NULL
binding	NULL
assessed	NULL
.	NULL

Specific	NULL
binding	NULL
was	NULL
not	NULL
detected	NULL
in	NULL
CML	NULL
cytosols	NULL
alone	NULL
.	NULL

Cytosols	NULL
obtained	NULL
from	NULL
a	NULL
mixture	NULL
of	NULL
T47D	NULL
and	NULL
CML	NULL
had	NULL
only	NULL
5	NULL
to	NULL
10	NULL
%	NULL
of	NULL
the	NULL
specific	NULL
binding	NULL
seen	NULL
in	NULL
cytosols	NULL
prepared	NULL
from	NULL
T47D	NULL
cells	NULL
alone	NULL
(	NULL
Chart	NULL
4	NULL
)	NULL
.	NULL

This	NULL
loss	NULL
of	NULL
binding	NULL
was	NULL
seen	NULL
whether	NULL
homog-enates	NULL
were	NULL
prepared	NULL
by	NULL
hypotonic	NULL
lysis	NULL
or	NULL
sonication	NULL
and	NULL
also	NULL
,	NULL
although	NULL
to	NULL
a	NULL
slightly	NULL
reduced	NULL
extent	NULL
,	NULL
when	NULL
binding	NULL
was	NULL
assayed	NULL
at	NULL
4°	NULL
,	NULL
rather	NULL
than	NULL
at	NULL
25°	NULL
.	NULL

T47D	NULL
ceils	NULL
were	NULL
also	NULL
prelabeled	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
-1,25-4	NULL
{	NULL
OH	NULL
)	NULL
>	NULL
Ds	NULL
mixed	NULL
with	NULL
CML	NULL
cells	NULL
and	NULL
homogenized	NULL
;	NULL
then	NULL
,	NULL
cytosols	NULL
were	NULL
prepared	NULL
and	NULL
incubated	NULL
under	NULL
the	NULL
same	NULL
time	NULL
and	NULL
temperature	NULL
conditions	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
specific	NULL
binding	NULL
in	NULL
T47D	NULL
cytosols	NULL
under	NULL
these	NULL
conditions	NULL
were	NULL
not	NULL
reduced	NULL
by	NULL
the	NULL
pres	NULL
1500	NULL
,	NULL
g	NULL
Z	NULL
oll	NULL
p	NULL
2	NULL
G	NULL
2	NULL
004	NULL
po	NULL
E	NULL
is	NULL
#	NULL
0	NULL
R	NULL
]	NULL
_-	NULL
F	NULL
'	NULL
``	NULL
A	NULL
g	NULL
§	NULL
&	NULL
ﬁ	NULL
7	NULL
7	NULL
S	NULL
r	NULL
e	NULL
2	NULL
|	NULL
go	NULL
R-	NULL
R	NULL
R	NULL
ha	NULL
ta	NULL
E	NULL
unoccupied	NULL
receptor	NULL
occupied	NULL
receptor	NULL
Chart	NULL
4	NULL
.	NULL

Effect	NULL
of	NULL
CML	NULL
cytosol	NULL
on	NULL
specific	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
{	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
binding	NULL
in	NULL
T47D	NULL
.	NULL

Cytosots	NULL
were	NULL
from	NULL
T47D	NULL
cells	NULL
alone	NULL
(	NULL
@	NULL
)	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
CML	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
}	NULL
-1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
to	NULL
unoccupied	NULL
receptors	NULL
was	NULL
assessed	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
100-fold	NULL
excess	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
,	NULL
at	NULL
either	NULL
25°	NULL
(	NULL
40	NULL
min	NULL
)	NULL
or	NULL
4°	NULL
(	NULL
3	NULL
hr	NULL
)	NULL
,	NULL
with	NULL
separation	NULL
of	NULL
unbound	NULL
steroid	NULL
by	NULL
charcoal	NULL
.	NULL

For	NULL
occupied	NULL
receptors	NULL
,	NULL
T47D	NULL
cells	NULL
were	NULL
prelabeled	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
-1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
:	NULL
D	NULL
;	NULL
+	NULL
100-fold	NULL
excess	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
:	NULL
Ds	NULL
,	NULL
and	NULL
cytosols	NULL
prepared	NULL
with	NULL
or	NULL
without	NULL
the	NULL
addition	NULL
of	NULL
CML	NULL
cells	NULL
were	NULL
incubated	NULL
gr	NULL
?	NULL

$	NULL
21	NULL
at	NULL
25°	NULL
and	NULL
then	NULL
charcoal	NULL
treated	NULL
.	NULL

Columns	NULL
,	NULL
mean	NULL
of	NULL
triplicate	NULL
estimations	NULL
;	NULL
3629	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
JIO	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

H.	NULL
C.	NULL
Freake	NULL
et	NULL
al	NULL
.	NULL

Table	NULL
1	NULL
Specific	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
Ds	NULL
binding	NULL
and	NULL
differentiation	NULL
induced	NULL
by	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
Ds	NULL
in	NULL
leukemia	NULL
cells	NULL
For	NULL
assessment	NULL
of	NULL
differentiation	NULL
,	NULL
the	NULL
leukemia	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
5	NULL
days	NULL
in	NULL
Iscove	NULL
's	NULL
modified	NULL
Dulbecco	NULL
's	NULL
minimum	NULL
essential	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
human	NULL
plasma	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
(	NULL
2	NULL
x	NULL
107°	NULL
m	NULL
)	NULL
.	NULL

Proportion	NULL
(	NULL
%	NULL
)	NULL
of	NULL
cells	NULL
containing	NULL
a-naphthy	NULL
!	NULL

acetate	NULL
es-1,25	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
terase	NULL
[	NULL
1,25-	NULL
DinCinQ	NULL
Nmex	NULL
(	NULL
OH	NULL
)	NULL
»	NULL
Ds	NULL
treated/	NULL
Disease	NULL
(	NULL
fmol/10	NULL
``	NULL
cells	NULL
)	NULL
control	NULL
]	NULL
n	NULL
CML	NULL
(	NULL
chronic	NULL
phase	NULL
)	NULL
18	NULL
+32	NULL
66	NULL
+	NULL
5/18	NULL
+	NULL
3	NULL
6	NULL
CML	NULL
(	NULL
acute	NULL
phase	NULL
)	NULL
7.2	NULL
+	NULL
1.5	NULL
``	NULL
16	NULL
+	NULL
4/20	NULL
+5	NULL
4	NULL
AML	NULL
2.6	NULL
+	NULL
0.8°	NULL
15+	NULL
6/18	NULL
+	NULL
3	NULL
4	NULL
*	NULL
Mean	NULL
+	NULL
S.E	NULL
.	NULL

ZResuﬂdiffersfrom	NULL
the	NULL
CML	NULL
(	NULL
chronic	NULL
phase	NULL
)	NULL
value	NULL
at	NULL
p	NULL
<	NULL
0.01	NULL
.	NULL

Result	NULL
differs	NULL
from	NULL
the	NULL
CML	NULL
(	NULL
chronic	NULL
phase	NULL
)	NULL
value	NULL
at	NULL
p	NULL
<	NULL
0.001	NULL
(	NULL
Student	NULL
t	NULL
test	NULL
,	NULL
2-tailed	NULL
)	NULL
.	NULL

ence	NULL
of	NULL
CML	NULL
cytosols	NULL
(	NULL
Chart	NULL
4	NULL
)	NULL
,	NULL
thus	NULL
suggesting	NULL
that	NULL
occupation	NULL
of	NULL
the	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
.D	NULL
;	NULL
receptor	NULL
prevents	NULL
its	NULL
inactivation	NULL
by	NULL
CML	NULL
cytosols	NULL
.	NULL

The	NULL
studies	NULL
reported	NULL
above	NULL
were	NULL
performed	NULL
using	NULL
mononuclear	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
CML	NULL
in	NULL
the	NULL
chronic	NULL
phase	NULL
of	NULL
their	NULL
disease	NULL
.	NULL

Using	NULL
a	NULL
single	NULL
saturating	NULL
dose	NULL
assay	NULL
,	NULL
specific	NULL
uptake	NULL
of	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
by	NULL
cells	NULL
of	NULL
this	NULL
type	NULL
was	NULL
18.0	NULL
+	NULL
3.2	NULL
fmol/	NULL
10	NULL
``	NULL
cells	NULL
(	NULL
n	NULL
=	NULL
6	NULL
)	NULL
.	NULL

Cells	NULL
taken	NULL
from	NULL
patients	NULL
with	NULL
the	NULL
same	NULL
disease	NULL
,	NULL
but	NULL
in	NULL
acute	NULL
transformation	NULL
,	NULL
had	NULL
only	NULL
one-half	NULL
this	NULL
level	NULL
of	NULL
specific	NULL
uptake	NULL
,	NULL
and	NULL
those	NULL
from	NULL
patients	NULL
with	NULL
AML	NULL
accumulated	NULL
still	NULL
less	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

CML	NULL
cells	NULL
in	NULL
chronic	NULL
phase	NULL
reproducibly	NULL
differentiated	NULL
along	NULL
the	NULL
monocyte-macrophage	NULL
pathway	NULL
in	NULL
response	NULL
to	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
as	NULL
judged	NULL
by	NULL
a	NULL
fluoride-sensitive	NULL
positive	NULL
reaction	NULL
with	NULL
a-naphthyl	NULL
acetate	NULL
esterase	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Although	NULL
,	NULL
as	NULL
previously	NULL
observed	NULL
in	NULL
AML	NULL
(	NULL
14	NULL
)	NULL
,	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
CML	NULL
blast	NULL
crisis	NULL
or	NULL
AML	NULL
showed	NULL
some	NULL
spontaneous	NULL
monocytic	NULL
differentiation	NULL
upon	NULL
culture	NULL
in	NULL
vitro	NULL
,	NULL
this	NULL
differentiation	NULL
was	NULL
not	NULL
enhanced	NULL
by	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
.	NULL

DISCUSSION	NULL
The	NULL
uptake	NULL
of	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
by	NULL
mononuclear	NULL
cells	NULL
from	NULL
CML	NULL
patients	NULL
is	NULL
of	NULL
high	NULL
affinity	NULL
and	NULL
specific	NULL
to	NULL
this	NULL
active	NULL
metabolite	NULL
of	NULL
cholecalciferol	NULL
.	NULL

Furthermore	NULL
,	NULL
homogenization	NULL
of	NULL
cells	NULL
prelabeled	NULL
with	NULL
hormone	NULL
showed	NULL
that	NULL
the	NULL
specifically	NULL
bound	NULL
radioactivity	NULL
was	NULL
restricted	NULL
to	NULL
cytosols	NULL
and	NULL
nuclei	NULL
.	NULL

Sucrose	NULL
density	NULL
centrifugation	NULL
of	NULL
high-salt	NULL
cytosols	NULL
allowed	NULL
the	NULL
detection	NULL
of	NULL
a	NULL
3.5-	NULL
to	NULL
3.7S	NULL
peak	NULL
which	NULL
was	NULL
totally	NULL
abolished	NULL
when	NULL
cells	NULL
were	NULL
preincubated	NULL
with	NULL
100-fold	NULL
excess	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
,	NULL
but	NULL
only	NULL
slightly	NULL
reduced	NULL
when	NULL
25-OHD	NULL
;	NULL
was	NULL
the	NULL
competitor	NULL
.	NULL

These	NULL
data	NULL
,	NULL
particularly	NULL
when	NULL
considered	NULL
in	NULL
conjunction	NULL
with	NULL
our	NULL
evidence	NULL
for	NULL
biological	NULL
responses	NULL
to	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
Ds	NULL
,	NULL
clearly	NULL
suggest	NULL
that	NULL
CML	NULL
cells	NULL
contain	NULL
the	NULL
specific	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
receptor	NULL
with	NULL
the	NULL
same	NULL
characteristics	NULL
as	NULL
those	NULL
seen	NULL
in	NULL
classic	NULL
target	NULL
tissues	NULL
(	NULL
7	NULL
,	NULL
13	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Our	NULL
failure	NULL
to	NULL
detect	NULL
this	NULL
protein	NULL
in	NULL
standard	NULL
cytosol	NULL
preparations	NULL
suggested	NULL
that	NULL
homogenization	NULL
of	NULL
CML	NULL
cells	NULL
led	NULL
to	NULL
the	NULL
inactivation	NULL
of	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
receptors	NULL
,	NULL
either	NULL
by	NULL
proteolytic	NULL
degrada-tion	NULL
,	NULL
by	NULL
chemical	NULL
modification	NULL
,	NULL
or	NULL
by	NULL
blocking	NULL
of	NULL
the	NULL
binding	NULL
site	NULL
by	NULL
an	NULL
alternative	NULL
endogenous	NULL
ligand	NULL
.	NULL

We	NULL
therefore	NULL
investigated	NULL
the	NULL
effects	NULL
of	NULL
addition	NULL
of	NULL
CML	NULL
cytosol	NULL
to	NULL
the	NULL
1,25-	NULL
{	NULL
OH	NULL
;	NULL
)	NULL
Ds	NULL
receptor	NULL
content	NULL
of	NULL
T47D	NULL
cell	NULL
cytosols	NULL
.	NULL

This	NULL
led	NULL
to	NULL
a	NULL
reduction	NULL
of	NULL
approximately	NULL
90	NULL
%	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
specific	NULL
binding	NULL
measured	NULL
in	NULL
T47D	NULL
cytosols	NULL
.	NULL

The	NULL
loss	NULL
of	NULL
binding	NULL
occurred	NULL
at	NULL
4°	NULL
as	NULL
well	NULL
as	NULL
25°	NULL
,	NULL
and	NULL
increasing	NULL
the	NULL
concentration	NULL
of	NULL
Trasylol	NULL
in	NULL
the	NULL
buffer	NULL
did	NULL
not	NULL
permit	NULL
the	NULL
detection	NULL
of	NULL
receptor	NULL
in	NULL
CML	NULL
cytosols	NULL
.	NULL

It	NULL
3630	NULL
therefore	NULL
seemed	NULL
unlikely	NULL
that	NULL
enzymatic	NULL
degradation	NULL
was	NULL
responsible	NULL
for	NULL
the	NULL
receptor	NULL
loss	NULL
.	NULL

When	NULL
receptors	NULL
in	NULL
T47D	NULL
cells	NULL
were	NULL
occupied	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
}	NULL
-1,25	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
CML	NULL
cytosol	NULL
,	NULL
a	NULL
reduction	NULL
in	NULL
the	NULL
binding	NULL
subsequently	NULL
assayed	NULL
did	NULL
not	NULL
occur	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
inactivation	NULL
process	NULL
is	NULL
likely	NULL
to	NULL
involve	NULL
parts	NULL
of	NULL
the	NULL
receptor	NULL
molecule	NULL
at	NULL
or	NULL
near	NULL
the	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
binding	NULL
site	NULL
,	NULL
which	NULL
are	NULL
protected	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
ligand	NULL
.	NULL

The	NULL
exact	NULL
nature	NULL
of	NULL
this	NULL
process	NULL
awaits	NULL
further	NULL
investigation	NULL
;	NULL
a	NULL
number	NULL
of	NULL
agents	NULL
are	NULL
known	NULL
which	NULL
inactivate	NULL
the	NULL
unoccupied	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
receptor	NULL
,	NULL
while	NULL
not	NULL
affecting	NULL
the	NULL
hormone-bound	NULL
form	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
the	NULL
sulfhydryl	NULL
alkylating	NULL
agent	NULL
N-ethylmaleimide	NULL
(	NULL
21	NULL
)	NULL
.	NULL

If	NULL
our	NULL
interpretation	NULL
of	NULL
these	NULL
results	NULL
is	NULL
correct	NULL
and	NULL
CML	NULL
cells	NULL
contain	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
receptors	NULL
which	NULL
are	NULL
not	NULL
routinely	NULL
measurable	NULL
in	NULL
cytosols	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
other	NULL
cells	NULL
may	NULL
possess	NULL
receptors	NULL
which	NULL
have	NULL
not	NULL
been	NULL
detected	NULL
for	NULL
similar	NULL
reasons	NULL
.	NULL

Previous	NULL
quantitation	NULL
of	NULL
receptors	NULL
in	NULL
established	NULL
target	NULL
tissues	NULL
may	NULL
be	NULL
inaccurate	NULL
,	NULL
since	NULL
the	NULL
levels	NULL
measured	NULL
would	NULL
represent	NULL
a	NULL
balance	NULL
between	NULL
the	NULL
intrinsic	NULL
content	NULL
and	NULL
the	NULL
inactivating	NULL
capacity	NULL
of	NULL
the	NULL
tissue	NULL
.	NULL

However	NULL
,	NULL
addition	NULL
of	NULL
cytosol	NULL
prepared	NULL
from	NULL
breast	NULL
tumors	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
diminish	NULL
the	NULL
levels	NULL
of	NULL
receptor	NULL
seen	NULL
in	NULL
T47D	NULL
cytosois	NULL
.	NULL
``	NULL

Cells	NULL
from	NULL
patients	NULL
with	NULL
either	NULL
AML	NULL
or	NULL
CML	NULL
in	NULL
acute	NULL
transformation	NULL
take	NULL
up	NULL
less	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
than	NULL
CML	NULL
cells	NULL
in	NULL
chronic	NULL
phase	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
more	NULL
primitive	NULL
cells	NULL
do	NULL
not	NULL
,	NULL
in	NULL
our	NULL
experience	NULL
,	NULL
differentiate	NULL
in	NULL
response	NULL
to	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
possession	NULL
of	NULL
adequate	NULL
levels	NULL
of	NULL
receptor	NULL
is	NULL
necessary	NULL
for	NULL
the	NULL
occurrence	NULL
of	NULL
the	NULL
biological	NULL
effect	NULL
.	NULL

It	NULL
also	NULL
suggests	NULL
that	NULL
the	NULL
amount	NULL
of	NULL
receptor	NULL
present	NULL
in	NULL
myeloid	NULL
leukemic	NULL
cells	NULL
varies	NULL
with	NULL
their	NULL
state	NULL
of	NULL
maturity	NULL
and	NULL
that	NULL
more	NULL
primitive	NULL
,	NULL
less	NULL
differentiated	NULL
cells	NULL
have	NULL
not	NULL
yet	NULL
developed	NULL
their	NULL
capacity	NULL
to	NULL
respond	NULL
to	NULL
1,25	NULL
{	NULL
OH	NULL
)	NULL
Ds	NULL
.	NULL

Preliminary	NULL
results	NULL
indicate	NULL
that	NULL
a	NULL
similar	NULL
receptor	NULL
exists	NULL
in	NULL
marrow	NULL
cells	NULL
taken	NULL
from	NULL
normal	NULL
donors	NULL
.	NULL

This	NULL
is	NULL
,	NULL
in	NULL
any	NULL
case	NULL
,	NULL
likely	NULL
since	NULL
the	NULL
distribution	NULL
of	NULL
myeloid	NULL
cell	NULL
types	NULL
in	NULL
chronic-phase	NULL
CML	NULL
marrow	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
found	NULL
in	NULL
normal	NULL
marrow	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
determination	NULL
of	NULL
which	NULL
particular	NULL
normal	NULL
and	NULL
transformed	NULL
human	NULL
blood	NULL
cells	NULL
are	NULL
targets	NULL
for	NULL
1,25-	NULL
{	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
is	NULL
now	NULL
proceeding	NULL
.	NULL

When	NULL
normal	NULL
or	NULL
leukemic	NULL
progenitor	NULL
cells	NULL
from	NULL
human	NULL
bone	NULL
marrow	NULL
differentiate	NULL
into	NULL
more	NULL
mature	NULL
forms	NULL
,	NULL
their	NULL
ability	NULL
to	NULL
proliferate	NULL
usually	NULL
decreases	NULL
.	NULL

Consequently	NULL
,	NULL
some	NULL
approaches	NULL
to	NULL
leukemia	NULL
therapy	NULL
are	NULL
now	NULL
directed	NULL
towards	NULL
differentiating	NULL
the	NULL
tumor	NULL
cells	NULL
rather	NULL
than	NULL
simply	NULL
killing	NULL
them	NULL
(	NULL
15	NULL
)	NULL
.	NULL

1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
inhibits	NULL
proliferation	NULL
of	NULL
HL6O	NULL
cells	NULL
in	NULL
vitro	NULL
(	NULL
12	NULL
,	NULL
19	NULL
)	NULL
.	NULL

The	NULL
growth	NULL
of	NULL
M1	NULL
mouse	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
is	NULL
also	NULL
inhibited	NULL
by	NULL
1,25-	NULL
{	NULL
OH	NULL
)	NULL
Ds	NULL
in	NULL
vitro	NULL
(	NULL
1	NULL
)	NULL
,	NULL
and	NULL
the	NULL
same	NULL
phenomenon	NULL
occurs	NULL
in	NULL
vivo	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
experimental	NULL
use	NULL
of	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
in	NULL
therapy	NULL
of	NULL
some	NULL
forms	NULL
of	NULL
leukemia	NULL
and	NULL
preleukemia	NULL
must	NULL
now	NULL
be	NULL
considered	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
Dr.	NULL
J.	NULL
M.	NULL
Gokiman	NULL
for	NULL
permission	NULL
to	NULL
study	NULL
patients	NULL
under	NULL
his	NULL
care	NULL
,	NULL
Professor	NULL
lain	NULL
Macintyre	NULL
for	NULL
helpful	NULL
discussions	NULL
,	NULL
and	NULL
M.	NULL
Bowe	NULL
and	NULL
D.	NULL
Simmonds	NULL
for	NULL
typing	NULL
the	NULL
manuscript	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Abe	NULL
,	NULL
E.	NULL
,	NULL
Miyaura	NULL
,	NULL
C.	NULL
,	NULL
Sakagami	NULL
,	NULL
H.	NULL
,	NULL
Takeda	NULL
,	NULL
M.	NULL
,	NULL
Konna	NULL
,	NULL
K.	NULL
,	NULL
Yamazaki	NULL
,	NULL
T.	NULL
,	NULL
Yoshiki	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Suda	NULL
,	NULL
T.	NULL
Differentiation	NULL
of	NULL
mouse	NULL
myeloid	NULL
leukaemia	NULL
cells	NULL
induced	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
Ds	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
78	NULL
:	NULL
4990-	NULL
4994	NULL
,	NULL
1981.	NULL
.	NULL

2	NULL
.	NULL

Bar-Shavit	NULL
,	NULL
Z.	NULL
,	NULL
Teitelbaum	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Retisma	NULL
,	NULL
P.	NULL
,	NULL
Hall	NULL
,	NULL
A.	NULL
,	NULL
Pegg	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
Trial	NULL
,	NULL
J.	NULL
,	NULL
®	NULL
J.	NULL
Iwasaki	NULL
and	NULL
H.	NULL
C.	NULL
Freake	NULL
,	NULL
unpublished	NULL
results	NULL
.	NULL

CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

44	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

10	NULL
.	NULL

1.	NULL
and	NULL
Kahn	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

Induction	NULL
of	NULL
monocytic	NULL
differentiation	NULL
and	NULL
bone	NULL
resorption	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
Ds	NULL
.	NULL

Proc	NULL
.	NULL

Nati	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
80	NULL
:	NULL
5907-5911	NULL
,	NULL
1983.	NULL
.	NULL

Colston	NULL
,	NULL
K.	NULL
,	NULL
Colston	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Feldman	NULL
,	NULL
D.	NULL
1,25-Dinydroxy-vitamin	NULL
Ds	NULL
,	NULL
and	NULL
malignant	NULL
melanoma	NULL
:	NULL
the	NULL
presence	NULL
of	NULL
and	NULL
inhibition	NULL
of	NULL
cell	NULL
growth	NULL
in	NULL
culture	NULL
.	NULL

Endocrinology	NULL
,	NULL
108	NULL
:	NULL
1083-1086	NULL
,	NULL
1981.	NULL
.	NULL

Colston	NULL
,	NULL
K.	NULL
,	NULL
Colston	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Fiekdsteel	NULL
,	NULL
A.	NULL
H.	NULL
,	NULL
and	NULL
Feldman	NULL
,	NULL
D.	NULL
1,25-Dihydroxy-	NULL
vitamin	NULL
D3	NULL
receptors	NULL
in	NULL
human	NULL
epithelial	NULL
cancer	NULL
cell	NULL
lines	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
42	NULL
:	NULL
856-859	NULL
,	NULL
1982.	NULL
.	NULL

Eisman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Suva	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
Sher	NULL
,	NULL
E.	NULL
,	NULL
Pearce	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Funder	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
and	NULL
Martin	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

Frequency	NULL
of	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
receptor	NULL
in	NULL
human	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
41	NULL
:	NULL
5121-5124	NULL
,	NULL
1981.	NULL
.	NULL

Frampton	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Suva	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
Eisman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Findlay	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Moore	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
Moseley	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Martin	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

Presence	NULL
of	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
in	NULL
established	NULL
human	NULL
cancer	NULL
cell	NULL
lines	NULL
in	NULL
culture	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
42	NULL
:	NULL
receptors	NULL
1116-1119	NULL
,	NULL
1982.	NULL
.	NULL

Franceschi	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
Simpson	NULL
,	NULL
R.	NULL
U.	NULL
,	NULL
and	NULL
DeLuca	NULL
,	NULL
H.	NULL
F.	NULL
Binding	NULL
proteins	NULL
for	NULL
vitamin	NULL
D	NULL
metabolites	NULL
:	NULL
serum	NULL
carriers	NULL
and	NULL
intracellular	NULL
receptors	NULL
.	NULL

Arch	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

2170	NULL
:	NULL
1-13	NULL
,	NULL
1981.	NULL
.	NULL

Freake	NULL
,	NULL
H.C.	NULL
,	NULL
Marcocci	NULL
,	NULL
C.	NULL
,	NULL
Iwasaki	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Macintyre	NULL
,	NULL
I1	NULL
.	NULL

1,25-Dinydroxyvi-	NULL
tamin	NULL
D	NULL
;	NULL
specifically	NULL
binds	NULL
to	NULL
a	NULL
human	NULL
breast	NULL
cell	NULL
line	NULL
and	NULL
stimulates	NULL
growth	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
107	NULL
:	NULL
1131-1138	NULL
,	NULL
1981.	NULL
.	NULL

Freake	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
Spanos	NULL
,	NULL
E.	NULL
,	NULL
Eisman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Galasko	NULL
,	NULL
C.	NULL
S.	NULL
G.	NULL
,	NULL
Martin	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
and	NULL
Macintyre	NULL
,	NULL
1	NULL
.	NULL

Specific	NULL
binding	NULL
of	NULL
1,25-dihnydroxyvitamin	NULL
D	NULL
,	NULL
in	NULL
the	NULL
VX2	NULL
carci-noma	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
97	NULL
:	NULL
1505-1511	NULL
,	NULL
1980	NULL
.	NULL

Honma	NULL
,	NULL
Y.	NULL
,	NULL
Hozumi	NULL
,	NULL
M.	NULL
,	NULL
Abe	NULL
,	NULL
E.	NULL
,	NULL
Konno	NULL
,	NULL
K.	NULL
,	NULL
Fukushima	NULL
,	NULL
M.	NULL
,	NULL
Hata	NULL
,	NULL
S.	NULL
,	NULL
Nishi	NULL
,	NULL
Y.	NULL
,	NULL
DeLuca	NULL
,	NULL
H.	NULL
F.	NULL
,	NULL
and	NULL
Suda	NULL
,	NULL
T.	NULL
1,25-Dihydroxy-vitamin	NULL
Ds	NULL
and	NULL
1	NULL
a-hydroxyvitamin	NULL
D	NULL
;	NULL
proiong	NULL
survival	NULL
time	NULL
of	NULL
mice	NULL
inoculated	NULL
with	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
80	NULL
:	NULL
201-204	NULL
,	NULL
1983	NULL
.	NULL

Majeska	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
and	NULL
Rodan	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
,	NULL
on	NULL
alkaline	NULL
phosphatase	NULL
in	NULL
osteoblastic	NULL
osteosarcoma	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
257	NULL
:	NULL
3362-3365	NULL
,	NULL
1982	NULL
.	NULL

AUGUST	NULL
1984	NULL
12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

21.	NULL
.	NULL

Yam	NULL
,	NULL
L.	NULL
T.	NULL
,	NULL
Li	NULL
,	NULL
C.	NULL
Y.	NULL
,	NULL
and	NULL
Crosby	NULL
,	NULL
W.	NULL
H.	NULL
Specific	NULL
Uptake	NULL
of	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
.D	NULL
;	NULL
by	NULL
CML	NULL
Cells	NULL
McCarthy	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
San	NULL
Miguel	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Freake	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
Green	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
Zola	NULL
,	NULL
H.	NULL
,	NULL
Catovsky	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Goldman	NULL
,	NULL
J.	NULL
M.	NULL
1,25-Dinydroxyvitamin	NULL
D	NULL
,	NULL
inhibits	NULL
prolifera-	NULL
tion	NULL
of	NULL
human	NULL
promyelocytic	NULL
leukaemia	NULL
(	NULL
HL60	NULL
)	NULL
cells	NULL
and	NULL
induces	NULL
monocyte-differentiation	NULL
in	NULL
HLGO	NULL
and	NULL
normal	NULL
human	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

Leuk	NULL
.	NULL

Res	NULL
.	NULL

,	NULL
7	NULL
:	NULL
51-55	NULL
,	NULL
1983	NULL
.	NULL

Norman	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
Rother	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Orci	NULL
,	NULL
L.	NULL
The	NULL
vitamin	NULL
D	NULL
endocrine	NULL
system	NULL
:	NULL
stemdmetaboﬁsm	NULL
hormone	NULL
receptors	NULL
and	NULL
biological	NULL
response	NULL
(	NULL
calcium	NULL
bind	NULL
ing	NULL
proteins	NULL
)	NULL
.	NULL

Endocrinol	NULL
.	NULL

Rev	NULL
.	NULL

,	NULL
3	NULL
:	NULL
331-366	NULL
,	NULL
1982	NULL
.	NULL

Palu	NULL
,	NULL
G.	NULL
,	NULL
Powles	NULL
,	NULL
R.	NULL
,	NULL
Selby	NULL
,	NULL
P.	NULL
,	NULL
Summersgill	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
and	NULL
Alexander	NULL
,	NULL
P.	NULL
Patterns	NULL
ofmaturaﬁonmshontermwltureofhwnanaanemyelodleukaermccels	NULL
Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
40	NULL
:	NULL
719-730	NULL
,	NULL
1979	NULL
.	NULL

Sachs	NULL
,	NULL
L.	NULL
The	NULL
differentiation	NULL
of	NULL
myeloid	NULL
leukaemia	NULL
cells	NULL
:	NULL
new	NULL
possibilities	NULL
for	NULL
therapy	NULL
?	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Haematol	NULL
.	NULL

,	NULL
40	NULL
:	NULL
509-517	NULL
,	NULL
1978	NULL
.	NULL

Scatchard	NULL
,	NULL
G.	NULL
The	NULL
attractions	NULL
of	NULL
proteins	NULL
for	NULL
small	NULL
molecules	NULL
and	NULL
ions	NULL
.	NULL

Ann	NULL
.	NULL

NY	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

,	NULL
51	NULL
:	NULL
660-672	NULL
,	NULL
1949	NULL
.	NULL

Shaw	NULL
,	NULL
M.	NULL
T.	NULL
Cliriealandhaematologtcalmmfestamofmmrmmalphase	NULL
In	NULL
:	NULL
M.	NULL
T.Shaw	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Chronic	NULL
Granulocytic	NULL
Leukaemia	NULL
,	NULL
pp	NULL
.	NULL

169-188	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Praeger	NULL
Publishers	NULL
,	NULL
1982	NULL
.	NULL

Sher	NULL
,	NULL
E.	NULL
,	NULL
Eisman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Moseley	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
andMarth	NULL
J.	NULL
Whole-cell	NULL
uptake	NULL
and	NULL
nudearloeaisaﬁmof125—dihydro	NULL
by	NULL
breast	NULL
cancer	NULL
cells	NULL
(	NULL
T47D	NULL
)	NULL
in	NULL
culture	NULL
.	NULL

Biochem	NULL
.	NULL

J.	NULL
,	NULL
200	NULL
;	NULL
315-320	NULL
,	NULL
1981	NULL
.	NULL

Tanaka	NULL
,	NULL
H.	NULL
,	NULL
Abe	NULL
,	NULL
E.	NULL
,	NULL
Miyaura	NULL
,	NULL
C.	NULL
,	NULL
Kuribayashi	NULL
,	NULL
R.	NULL
,	NULL
Konno	NULL
,	NULL
K.	NULL
,	NULL
Nishii	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Suda	NULL
,	NULL
T.	NULL
A	NULL
human	NULL
myeloid	NULL
leukaemia	NULL
line	NULL
(	NULL
HL6O	NULL
)	NULL
;	NULL
the	NULL
of	NULL
cytosol	NULL
and	NULL
induction	NULL
of	NULL
differentiation	NULL
.	NULL

Biochem	NULL
.	NULL

J.	NULL
,	NULL
204	NULL
:	NULL
713-719	NULL
,	NULL
1982.	NULL
.	NULL

Walters	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Hunziker	NULL
,	NULL
W.	NULL
,	NULL
Konami	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Norman	NULL
,	NULL
A.	NULL
W.	NULL
Factors	NULL
affecting	NULL
the	NULL
distribution	NULL
and	NULL
stability	NULL
of	NULL
unoccupied	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
receptors	NULL
.	NULL

J.	NULL
Recep	NULL
.	NULL

Res	NULL
.	NULL

,	NULL
2	NULL
:	NULL
331-346	NULL
,	NULL
1982	NULL
.	NULL

Wecksler	NULL
,	NULL
W.	NULL
R.	NULL
,	NULL
and	NULL
Norman	NULL
,	NULL
W.	NULL
A.	NULL
Biochemical	NULL
properties	NULL
of	NULL
1,25-dihnydroxy-identification	NULL
of	NULL
vnammDreoeptors	NULL
J.	NULL
Steroid	NULL
.	NULL

Biochem	NULL
.	NULL

13	NULL
:	NULL
977-989	NULL
,	NULL
1980	NULL
.	NULL

Cytochemical	NULL
monocytes	NULL
and	NULL
granulocytes	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Pathol	NULL
.	NULL

,	NULL
55	NULL
:	NULL
283-290	NULL
,	NULL
1971	NULL
.	NULL

3631	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Specific	NULL
Uptake	NULL
of	NULL
1,25-Dihydroxycholecalciferol	NULL
by	NULL
Human	NULL
Chronic	NULL
Myeloid	NULL
Leukemia	NULL
Cells	NULL
H.	NULL
C.	NULL
Freake	NULL
,	NULL
J.	NULL
Iwasaki	NULL
and	NULL
D.	NULL
M.	NULL
McCarthy	NULL
Cancer	NULL
Res	NULL
1984	NULL
;	NULL
44:3627-3631	NULL
.	NULL

Updated	NULL
version	NULL
_	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/44/8/3627	NULL
E-mail	NULL
alerts	NULL
_	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

Reprints	NULL
and	NULL
_	NULL
To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Subscriptions	NULL
_	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

Permissions	NULL
_	NULL
To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/44/8/3627	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

